N THE EARLY 1980s, a new molecule, CD30, was identified using a specific monoclonal antibody (MoAb; Ki-1) raised after immunization with L246 cell lines derived from a patient with Hodgkin's disease (HD) . ' The precise function of this molecule, a new member of the nerve growth factor gene family, ' is not yet known, but it may participate in the early phases of lymphoid activation. Although CD30 is not a specific Reed-Stemberg (RS) cell marker, analysis of its expression has assumed an important role in the differential diagnosis of HD.3 Moreover, the systematic use of immunohistochemical techniques and the analysis of antigens preferentially expressed by RS cells, such as CD30, have permitted the identification of a previously unrecognized category of non-Hodgkin's lymphoma (NHL), now designated CD30 (Ki-1)-positive anaplastic large-cell lymphoma (ALCL). 4 These neoplasms represent a morphologically distinct type of large-cell lymphoma that is distinguished phenotypically by expression of the CD30 antigen. Before the discovery of this antigen, these lymphomas were not recognized as a distinct clinicopathologic entity and instead were variously misinterpreted as true histiocytic lymphoma, malignant histiocytosis, nodular sclerosis or lymphocyte-depleted HD, malignant melanoma, metastatic carcinoma of unknown origin, and malignant fibrous histiocyt~m a .~
The lymphoid origin of these ALCLs has been shown by their expression of B-and/or T-cell lineage-restricted antigens and/or the presence of clonal Ig or T-cell receptor (TCR) gene re arrangement^.^ However, T-and B-cell antigens and clonal Ig and TCR gene rearrangements cannot be documented in approximately 30% of ALCLS,~ perhaps indicating that a subset of ALCLs are derived from precursor B and T cells that have not yet undergone Ig or TCR gene rearrangement. The lymphoid origin of these neoplasms is also supported by the observation that clonal Epstein-Barr virus (EBV)-specific and human T-cell lymphotropic virus type I (HTLV-I) proviral sequences* are detectable in some CD30+ ALCLs. However, although the lymphoid origin of entity is certain, its relationship with other hematologic neoplasms, particularly with HD, remains controversial. Some clinicopathologic studies suggest that We identified abnormal c-myc gene products in 6 of 18 cases (33%) of ALCL. On the other hand, the bcl-2 and Fib genes were not rearranged and K-, N-, and H-ras gene somatic mutations were not found. Significant levels of p53 protein expression were found in more than 60% of ALCLs, but only a single ALCL carried a p53 gene mutation (exon 5). Only 3 ALCL cases, all occurring in human immunodeficiency virusinfected patients, were positive for EBV genomes. On the other hand, contrary to previous findings, no HTLV-I products could be identified. Despite the fact that the c-myc proto-oncogene appears to be frequently altered in ALCL, no pathognomonic abnormality could be identified and therefore additional studies and new strategies should be designed to identify the pathogenetic mechanisms involved in the development of ALCL. 0 1994 by The American Society of Hematology.
HD and ALCL may represent different morphologic expressions of the same pathologic process. ' Alterations of proto-oncogene loci, including mutations, amplifications, and chromosomal translocations and deletions, are consistently and specifically associated with several types of human neoplasms and are strongly implicated in tumorigenesis." In lymphoid tumors, a variety of lesions involving "dominantly acting" oncogenes activated either by chromosomal translocation (c-myc in high-grade NHL, bcl-2 in low-and intermediate-grade NHL) or by point mutations (N-rus in acute lymphoblastic leukemia [ALL] and multiple myeloma) have been documented." Furthermore, tumor suppressor genes have also been recently shown to play an important role in the pathogenesis of human neoplasms. In fact, the disruption or loss of these genes, namely, retinoblastoma (Rb) and p53, relieves the cell from certain negative regulatory signals." Whereas a large amount of information has been obtained on tumor suppressor gene lesions in multiple types of solid human tumors and in several human hematopoietic malignancies, relatively little is known concerning their potential involvement in ALCL.
In the present study, we have performed a comprehensive molecular analysis of a large, well-characterized panel of ALCLs to identify genetic abnormalities associated with the pathogenesis of ALCL. Our results indicate that the c -m y proto-oncogene appears to be relatively frequently involved in ALCLs, particularly in those of B-cell origin, and therefore may play a role in the pathogenesis of this distinct subtype of NHL. On the other hand, proto-oncogenes bcl-2, and H-, N-, and K-Rus do not appear to be activated and tumor suppressor genes p53 and Rb do not appear to be mutateddeleted in ALCL.
MATERIALS AND METHODS
Pathologic samples. A panel of 21 well-characterized cases of ALCL were selected from among cases processed in the surgical pathology laboratories of the Columbia Presbyterian and New York University Medical Centers.
In addition, we included three previously described CD30' lymphoblastoid cell lines derived from CD30+ ALCLs." Heparinized peripheral blood, bone marrow aspiration samples, and lymph node biopsy specimens were collected and processed as previously described.'* Representative portions of each tissue specimen were routinely fixed in buffered formalin, B5. or Bouin's; embedded in paraffin; and hematoxylin and eosin (H&E)-stained sections were prepared. The remaining portions were embedded in a cryopreservative solution (OCT compound; Miles, Elkhart. IN) and stored at -70°C. The diagnosis of ALCL was based on correlative analysis of the clinical, histopathologic, and immunophenotypic characteristics. The morphologic features included infiltration by large pleomorphic cells with abundant cytoplasm and irregularly shaped nuclei containing one or more prominent nucleoli, a high mitotic rate, sinusoidal spread, the presence of multinucleated cells often resembling RS cells, fibrosis, and numerous histiocytes intermingled with the tumor cells. Positive staining with monoclonal antibody Der-H2 (CD30) was required for the diagnosis of ALCL.
DNA extraction. Genomic DNA was extracted from cryopreserved mononuclear cell suspensions and tissue blocks using a salting-out procedure." An alternative procedure was used when a very limited amount of tissue was available, which yielded sufficient DNA for polymerase chain reaction (PCR) analysis only.I4 Briefly. three frozen sections were resuspended in 250 pL of a buffer (50 mmol/L KCI, 15 mmol/L Tris-Cl, 2.5 mmoVL MgCI,, 0.5%' Tween 20) containing 100 &mL of fresh proteinase K. This mixture was incubated for 45 minutes at 56°C to digest the cells and then for I O minutes at 95°C to inactivate the protease. The tubes were spun in a microcentrifuge for 30 minutes. The supernatant was then transferred to a new tube and the DNA quantitated spectrophotometrically.
Southern blot hybridization analysis and restriction fragment lengrh polymorphism (RFLP) analysis.
Five-microgram to 15-1.11: aliquots of genomic DNA were digested with the appropriate restriction endonucleases and handled according to Southern." The Ig heavy and light chain and T-cell receptor , L? chain (TP) genes were investigated using Ig heavy and K light chain joining region probes (JHIh; JK") and the constant TP gene region probe," respectively.
The organization of the c-myc locus was analyzed by hybridization of EcoRI, HindIII, and PVU digested DNAs to human c -m y MC413RC and PVU-PVU probes, respectively." P"-d(CTP) MC4l3RC-labeled filters were automatically scanned using a Beta scanner to evaluate the optical density of each corresponding band. Normalization was achieved by dividing the mvc values by the values obtained from the hybridization of the same filters using a bcl-2 probe as a control (pFLI). The bcl-2 and RBI loci were investigated as previously described.2"~22 Two highly polymorphic markers for loci on chromosome 17, pYNZ22.1" and p144D6,14 were used to assess the loss of heterozygosity in the p53 mutated case and p53 deletion in the nonmutated cases. OliSo,luc/~otide prirnrrs. Ail the oligonucleotides used tor PCR amplification in this study were synthesized by the solid-phase triester method. The first exon-first intron boundary of the c-rtryc gene was investigated using the following pairs of oligonucleotides: F5'. . and H-rus and p53 S to 9 exons have been previously described."." The presence of genomic EBV and HTLV-I sequences was investigated using DNA oligonucleotides corresponding to the BMRF-I EBV region" and to the GAG HTLV-I region." To investigate the possibility of MDM2 gene amplification, the following primers corresponding to known MDM2 gene sequence?" were used: MDM2-S; 5"ACCTCACAGATTCCA-GCTTC (nucleotides. 358 through 378); MDM2-3A, S'-TTCCTG-TAGATCATGGTATA (nucleotides, 610 through 630); and MDM2-38. 5"CTCCTTCTAGATGAGGTAGA (nucleotides, 780 through 800). Both MDM2-PCR products were cloned and sequenced to confirm their origin and specificity and then used in Southern blot analysis.
Single-strand conjornlation polymorphism (SSCP) anuly.sis. SSCP analysis was accomplished according to an adapted version of a previously reported
Cloning and sequenciq of PCR products. PCR products were cloned in the pCR I1 vector using the TA cloning system (lnvitrogen Co~p, San Diego, CA), following the manufacturer's instructions. DNA sequencing was performed directly from a small-scale plasmid preparation'" after determining the presence of an insert. The Sequenase version 2.0 (US Biochemical, Cleveland, OH) system was used. and a modification of the manufacturer's instructions was performed."' Inzmunohistochemical .staining and Feulgen procedures. The immunophenotype of the ALCLs had been determined at the time of diagnosis by immunohistochemical staining of frozen or paraffin tissue sections using a streptavidin-biotin immunoperoxidase technique (ABC) or an immunoalkaline phosphatase antialkaline phosphatase method (APAAP), and/or by direct and indirect immunofluorescent flow cytometry of isolated cells in suspension using the FACScan fluorescent-activated cell sorter (Becton Dickinson, Mountain View, CA)." MoAbs used to immunophenotype the cases of ALCL included OKT3 (CD3), OKT4 (CD4), OKT6 (CDI). OKT8
, Ki-67 (DAKO-PC; Dako Corporation, Santa Barbara, CA). and B I (CD20; Coulter Immunology, Hialeah, FL). p53 and Rb protein expression were investigated by immunohistochemical staining on acetone-chloroform fixed sections using anti-pS3 MoAb PAbl801" (p53 Ab-2; Oncogene Science, Inc. Uniondale, NY) and anti-RBI (Triton), respectively, in conjunction with ABC and APAAP techniques.
DNA content and S-G2 cell fractions were evaluated using 
RESULTS
Clinical characteristics. We investigated 21 cases of ALCL and three CD30+ lymphoblastoid cell lines derived from CD30+ ALCLs." The median age of the patients was 58 years, with a range of 18 to 86 years. The male to female ratio was 2.5: 1. Seven patients had extranodal disease (including two with ascites and two with primary skin lesions) and the remaining patients had local or generalized lymphadenopathy ( Table 1) . At least seven patients had liver and/ or spleen involvement, and two had lung nodules. Four of the patients (cases no. 15, 16, 17, and 21) had documented acquired immunodeficiency syndrome (AIDS).
Immunophenotypic and genotypic characteristics. The results of immunophenotypic analysis are shown in Table 1 . Briefly, all of the cases were CD30+, 70% were CD45', 80% were EMA', and all except one were CD15 (LeuM1)-negative. Based on the immunophenotypic characterization, a T-cell origin was likely in 8 cases, a B-cell origin in 10 cases, and 3 cases were indeterminate. These included 5 cases that did not express any B-or T-cell-restricted antigens, thus precluding definitive lineage assignment, and 2 cases lacking all lymphoid antigens. To confirm these data, Ig heavy and light chain and TCRP gene rearrangements were evaluated by Southern blot analysis using Ig heavy and light chain joining region probes (JH and JK) and a constant TCRP gene region probe (cPTCR). Clonal Ig heavy or light chain gene rearrangements were documented in only 5 cases: 2 expressing a B-cell phenotype and 3 expressing an indeterminate phenotype, including the 2 null cell ALCLs presenting as body cavity based lymphomas and occumng in patients with AIDS. Interestingly, three other cases expressing B-cell-restricted and/or -associated molecules exhibited the germline configuration for the Ig heavy or light chain genes, suggesting that these lymphomas may represent the neoplastic counterpart of immature or pre-B cells. On the other hand, 5 of 8 ALCLs expressing T-cell immunophenotypes displayed clonal TCRP gene rearrangements. In addition, a single clonal TCRP gene rearrangement could be found using EcoRI-and BamHI-digested DNAs in a phenotypically indeterminate case. Finally, all three ALCL cell lines (DHL, TS, and JB) exhibited clonal TCRP gene rearrangements, as previously reported." In summary, these data suggest that only a subgroup of ALCLs expressing Tor B-cell-restricted and/or -associated antigens undergo TCR or Ig gene rearrangement and therefore appear to represent the neoplastic counterpart of relatively mature T or B cells, whereas the remaining ALCLs may correspond to the neoplastic counterpart of immature T cells or pre-pre-B or pre-B cells.
DNA content and proliferation index. The DNA content was evaluated on Feulgen-stained frozen sections and/or tissue imprint preparations and then quantitatively investigated with a computerized image analyzer (CAS-200). Normal resting lymphocytes showed a diploid DNA content in all 21 cases. On the other hand, the DNA content of the ALCL cells was more heterogeneous. A single diploid population with or without a tetraploid population was found in 12 of For personal use only. on October 26, 2017. by guest www.bloodjournal.org From 
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Abbreviations: G, germline; R, rearranged; A, amplified; M, wild type; M, mutated; N. negative; P, positive.
18 cases, and a nondiploid population was found in 6 cases ( 3 aneuploid and 3 tetraploid). Interestingly, more than 15% of the neoplastic cells could be found in S-G2 phase in all the cases. These findings could be confirmed when the proliferation index was evaluated using MoAb Ki-67 that specifically detects a protein expressed in late Gl(Glb), S, and G2 phase.3' Proto-oncogene activation. The lack of information regarding oncogene activation in this unique group of neoplasms prompted us to investigate the possible presence of proto-oncogene rearrangement and somatic point mutation in ALCL. The bcl-2, c-myc, and H-, N-, K-rus proto-oncogenes were evaluated using Southern blot analysis and PCR-SSCP in association with DNA nucleotide sequencing of the cloned PCR fragments displaying abnormal gel migration.
The bcl-2 proto-oncogene is a unique member of the oncogene family. Contrary to the large majority of other protooncogenes that control cell proliferation, bcl-2 appears to be primarily involved in cell survival blocking programmed cell death.34 Notably, the most frequent translocation occurring in NHLs is the t(14; 18)(q32;q21).35. 36 The fact that bcl-2 gene rearrangements may occur in some HD3' and that HD may be related to ALCL prompted us to investigate bcl-2 translocation involving the major and minor cluster bcl-2 regions in ALCLs. Furthermore, we also investigated bcl-2 protein expression using a specific MoAb by an ABC immunohistochemical technique. No detectable rearrangements could be identified in any of 18 cases by Southem blot analysis and the neoplastic CD30+ cells expressed detectable bcl-2 protein in only 4 of 17 cases ( Table 2) . The results obtained from these combined approaches strongly suggest that the bcl-2 proto-oncogene is not involved in the pathogenesis of these neoplasms.
c-myc proto-oncogene activation, because of translocations involving chromosome 8, is characteristically found jn Burkitt's lymphoma, in L3 ALL, and in a subgroup of largecell lymphomas.'o~19~'"39 Two different mechanisms leading to deregulation and subsequent activation of c-myc have been described. c-myc activation in sporadic Burkitt's lymphomas and a subset of large-cell lymphomas is caused by c-myc gene truncations within the first exon, first intron, or flanlung sequences. On the other hand, in endemic Burkitt's lymphomas and in those cases presenting c-myc variant translocations [t(2;8) and t(8;22)], somatic point mutations or small rearrangements occurring within the regulatory regions of the c-rnyc gene spanning the first exon-first intron boundary are responsible for c-myc activation. These two distinct patterns can be efficiently investigated using Southern blot analysis and PCR-SSCP in association with DNA sequencing of the abnormally migrating PCR products, respectively. Using Southern blot analysis, we were able to identify c-myc gene rearrangement products (EcoRYHindIII and EcoRIA'VU) in two B-cell AWLS (1 HIV-negative and 1 HIV-positive patient, cases no. l l and 21) and c-rnyc amplification in a third case (case no. 16, HIV-positive; Fig lA, B, and C) . c-myc Table 11 .
four different oligonucleotide primers spanning 354 bp (27 16 through 3060) of this region were used. These two sets of oligoprimers were specifically chosen to investigate two different c-myc regions that have been shown to be altered in high numbers of endemic Burkitt's lymphoma and neoplasms carrying variant translocations (2743 through 2850 region involved in transcription elongation and 3010 through 3030 region known as c-myc MIF element). Using this approach, we observed abnormal gel migration patterns of the PCR-amplified fragment by SSCP analysis in 4 different patients. In particular, three aberrant band patterns were seen using the first set of oligoprimers spanning the 27 16 through 2891 region and two using the second set of oligoprimers spanning the 2803 through 3060 region (Fig 2A and B) . A single case (case no. 1 1) presented an abnormal SSCP pattern using both oligonucleotide primer sets. To confirm the presence of these mutations, we cloned the PCR products in pCR I1 vector and individual colonies with the expected PCR fragments were then sequenced. Several clones carrying mutated fragments, among unmutated ones, were identified in each case (Fig 3) . Every mutation was found within or in very close proximity to a region spanning 2750 to 2850 nucleotides (case no. Mutations occurring at codons 12, 13, and 61 of the Ras proto-oncogenes have been described in a large number of human neoplasms. In particular, among lymphoid neoplasms, ALLs and multiple myelomas often show Ras gene activation.25 Based on the fact that no information is available on Ras proto-oncogene activation in ALCL and that at least some ALCLs may be derived from immature B cells, we decided to investigate the presence of Ras gene mutations by PCWSSCP. Codons 12, 13, and 61 of the H-, K-, N-ras gene were studied, as previously d e s~r i b e d .~~.~~ However, we did not find any mutations in any of the 18 fresh ALCLs or in the three CD30' ALCL cell lines using this approach ( Table 2) .
Tumor suppressor gene inactivation. In the past few years, a large amount of information has been obtained regarding a new category of genes called tumor suppressor genes, namely, Rb and p53. These tumor suppressor genes have been recently shown to play an important role in the pathogenesis of human neoplasms. To precisely characterize p53 gene mutation and expression, we evaluated the expression of p53 protein(s) using specific MoAbs"' by immunohistochemistry and then studied the presence of mutations within p53 gene exons 5 to 9 by PCWSSCP. Nuclear p53 protein staining could be identified in 15 of 18 ALCLs and in 11 cases was seen in more than 30% of the neoplastic cells. Eight of these cases showed bright and intense staining. A large majority of cells (>40%) in all three ALCL cell lines showed strong nuclear staining. On the other hand, only a single case (case no. 2) of a total of 18 fresh ALCLs and three ALCL cell lines showed a mutation (within exon 5) after PCWSSCP and DNA sequencing. These data clearly indicate that a direct correlation between p53 protein expression and presence of p53 mutations does not exist in ALCL, contrary to that previously described for other human neoby the fact that wild-type p53 protein is potentially bound and stabilized by viral or other unknown proteins." Recently, it has been shown that the MDM-2 gene is often amplified in solid tumors and that overexpressed MDM-2 gene products can bind and inactivate wild-type p53 p r~t e i n ?~.~' Based on these findings, we studied the presence of MDM-2 gene amplification in HindIII-digested ALCL DNAs by Southern blot analysis using a specific cDNA probe. No MDM-2 gene amplifications could be found when the beta-scanned values obtained from HindIIIIMDM-Shybridized filters were normalized with the value derived from the same filter after hybridization with the pFLl probe (Bcl-2, control gene).
Recently, mutational inactivation of the Rb gene has been documented not only in Rb42 but also in a variety of other human tumors, indicating that the functional loss of the Rb gene may be involved in the initiation and/or progression of several human neoplasms:' Two different approaches were used to investigate the Rb gene in our ALCLs. First, we studied Rb protein expression by immunohistochemistry using a specific anti-Rb MoAb. Using this technique, we were able to demonstrate positive nuclear staining in a variable plasms~10.30.40 However, our negative results could be caused 
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percentage (10% to 60%) of neoplastic cells in all of the cases of ALCL. Therefore, these data indicate that no major loss of the Rb gene locus had occurred in these neoplasms. These immunohistochemical findings were corroborated by Southern blot analysis. In fact, when ALCL-digested DNAs were hybridized to two different cDNA probes corresponding to Rb exons I to 9 and I O to 27, no detectable Rb gene abnormalities could be identified.
EBV and HTLV-I viral infecrion. Clonal EBV-specific sequences and HTLV-I proviral sequences have been detected in some CD30' ALCLs. More precisely, EBV has been found in B-or T-cell ALCLs exclusively in lymph nodal cases:' whereas HTLV-I has been identified in a small number of cutaneous T-ALCLS.~ The presence of either EBV or HTLV-I in ALCLs is particularly important because some of their gene products have been shown to upregulate the expression of CD30.' In addition, as we mentioned above, viral gene products can bind to other cellular molecules, in particular to wild-type p53, modifying their physiologic functions. Therefore, we decided to investigate the presence of EBV (Barn W) and HTLV-I (Gag) by PCR using specific oligonucleotides. Using this approach, we were able to demonstrate the presence of EBV genomic sequences in 3 of I8 cases of ALCL, all occurring in HIV-infected patients ( Fig  4A) . Furthermore, their EBV clonality was also demonstrated by Southern blot analysis (data not shown). On the other hand, no HTLV-I PCR sequences could be specifically amplified, despite the fact that 3 of our 18 cases are cutaneous T-cell ALCL (Fig 4B) .
DISCUSSION
NHLs represent a large and heterogeneous group of neoplasms including multiple subgroups that possess characteristic morphologic, immunophenotypic, and cytogenetic features and often a unique pathogenesis. The systematic use of MoAbs against the CD30 antigen has permitted the identification of a previously unrecognized category of NHL now designated CD30 (Ki-I)-positive ALCL. Despite a great effort, very little is known concerning the molecular aberrations that may precede or be involved in the neoplastic transformation. The only exception is a newly described t(2;5) translocation apparently restricted to this neoplasm and often and uniquely identified in ALCLs of T-cell origin.".'" However, the gene(s) involved and possibly deregulated as a consequence of this translocation remain totally unknown.
In this study, we have shown that the c-my proto-oncogene is rearranged or mutated in a considerable number of ALCL cases, often of B-cell origin, indicating that a deregulated c-myc gene may play a crucial role in the tumorigenesis of these lesions and particularly in those of B-cell origin. On the other hand, bcl-2, K-, H-, and N-rus, p53, and Rb genes are not altered in ALCLs, and HTLV-I and EBV viruses appear only to be occasionally involved in their pathogenesis. A unique andor characteristic molecular abnormality could not be identified and thus it is possible to speculate that ALCLs may represent a heterogeneous group of NHLs with multiple, unique, and possibly lineage-related pathogenesis.
Two different mechanisms resulting in deregulation and For Interestingly, the c-myc proto-oncogene displayed some abnormality in both HIV-associated B-cell-derived ALCLs. This finding supports previous observations indicating that the c-myc proto-oncogene is often altered in HIV-associated B-cell NHLs. In particular, c-myc gene activation has been often described in HIV-associated Burkitt's and Burkitt's-like lymphomas (100%) and less frequently in large-cell (50%) and immunoblastic plasmacytoid (25%) Interestingly, EBV genomic sequences could be documented in both body cavity based lymphomas, indicating that these neoplasms more closely resemble large-cell and/or immunoblastic plasmacytoid than Burkitt's and Burkitt's-like lymphomas. The presence of surface and cytoplasmic CD30 molecules and the unique cytologic features of these cases justify their inclusion among the ALCLs and the hypothesis that they represent a distinct subgroup of them.
The presence of a significant number of cases carrying somatic mutation in the first exonhntron region of c-mvc is of particular interest. In fact, with the exception of Burkitt's lymphomas occurring in endemic areas and rare NHLs in Western countries carrying variant transIocations,j7 similar lesions have not been described in NHL. Interestingly, cmyc somatic point mutations always occur in association with c-myc translocations. Two possible scenarios can be hypothesized: ( I ) the somatic point mutations occur without c-myc translocations or (2) they occur with variant or new translocations. If the first hypothesis is correct, this will be the first time that these aberrations have been identified and therefore their potential pathogenetic role is totally speculative. In the second case, the c-myc mutations will occur concomitantly with the c-myc translocation(s) whose pathogenetic role is well established." Against this hypothesis is the fact that no translocations involving chromosome 8(q24) have been described in primary ALCLs; however, less information is available for secondary ALCLs. Based on the fact that a relatively large number of ALCLs in our panel had a Bcell phenotype, we cannot exclude the possibility that these neoplasms may have derived from sporadic NHLs carrying c-myc variant translocation(s).
However, regardless of the precise mechanism(s) responsible for c-myc activation, the observation that the c-myc proto-oncogene is potentially activated in a subgroup of ALCLs sheds some light on the pathogenesis of ALCLs. It is possible that, in addition to another unknown event, cmyc activation is a required step in the tumor progression of at least some ALCLs. If this is true, similar to Burkitt's lymphomas, c-myc activation would be the necessary step for the neoplastic transformation of a cell that has already acquired the first "hit." On the other hand, c-myc activation may represent a late event and therefore play a role in tumor progression rather than transformation. A similar scenario has been described in those lowhntermediate-grade B-cell lymphomas carrying bcl-2 rearrangements that eventually also acquire c-myc rearrangements and, as a consequence, become high-grade
In addition to the c-myc gene, the bcl-2 and N-, K-, Hms genes were also evaluated because (1) translocations involving the bcl-2 gene locus are the most common chromosomal aberrations occurring in NHL and (2) somatic point mutations of Rns family genes have been described in immature B-cell neoplasms as well as in well-differentiated lymphoid neoplasms such as multiple myeloma and plasmacytomas.'5 No detectable bcl-2 gene rearrangements were documented in our cases and, interestingly, when bcl-2 protein expression was investigated using an immunohisto- In the case containing p53 mutations, the high level of p53 expression can be explained as an increase in the half-life of the mutated pr~tein.~' However, the mechanism(s) responsible for the high level of expression in other cases of ALCL remains to be determined. Based on the fact that high levels of p53 expression can be detected in actively proliferating benign and neoplastic hematopoietic cells:' and the fact that high proliferation indices can be found in ALCL, it is reasonable to speculate that high expression of wild-type p53 may be related to cell-cycle-dependent mechanisms. However. this correlation does not indicate the potential mechanism(s) leading to p53 expression, and the relationship between these two events is not yet understood. Furthermore, alternative mechanisms may be implicated. It has been demonstrated that wild-type p53 can be inactivated when MDM-2 gene products bind to it.4' Similarly, p53 may bind viral proteins, such as EBV and HTLV-I products, becoming functionally inactive. Several studies have suggested that HTLV-I' and/or EBV6.' may be involved in the pathogenesis of ALCLs.
In our study, despite the presence of several T-cell ALCLs, some of which involved the skin, no HTLV-I gene products could be identified. These data fail to confirm previous findin& that have suggested that at least 30% of all ALCLs involving the skin are positive for HTLV-I. This discrepancy may be caused by ethnic differences (European v American) and/or by the small number of cases with primary skin involvement included in this study. On the other hand, the presence of EBV genomes by PCR and by Southern blot analysis (clonal band using internal repeat EBV probe, data not shown) was documented in 3 of 21 ALCL cases. Notably, all 3 cases showed a B-cell immunophenotype and occurred in HIV-positive men. Approximately 30% to 35% of all ALCLs have been documented to have neoplastic cells carrying EBV genomes and/or specific EBV products.'.' Little is known regarding the concomitant presence of other viruses and whether these patients were also HIV-positive. The pathogenetic role of EBV in human lymphoid neoplasms has been extensively studied and it appears to act at a crucial and perhaps the initial step in the transformation of human lymphoid neoplasm^.^^-^^ In particular, the presence of EBV and c-myc activation may be sufficient for cellular transform a t i~n .~' The fact that 2 of the 3 EBV-positive cases contained c-myc abnormalities is not coincidental, particularly in consideration of the fact that these individuals were HIVpositive.
In conclusion, we have extensively investigated the molecular organization of several proto-oncogenes and tumor suppressor genes in a large, well-characterized panel of ALCLs. Our findings indicate that the c-myc proto-oncogene is frequently altered and therefore potentially involved in the pathogenesis of these neoplasms and perhaps plays a crucial role in the tumorigenesis of ALCLs derived from normal B cells. On the other hand, known tumor suppressor genes, namely p53 and Rb, do not appear to be involved in the pathogenesis of ALCL. These findings indicate that the pathogenesis of this subgroup of NHL remains largely unknown. Additional studies and new strategies must be designed and initiated to identify the specific aberrations responsible for the unique phenotype and/or the pathogenesis of ALCL. 
